Cognitive Adverse Effects of Antiepileptic Drugs: Incidence, Mechanisms and Therapeutic Implications

CNS Drugs

Volumn 5, Issue 5, 1996, Pages 358-368

  Kälviäinen, Reetta ^a   Äikiä, Marja ^a   Riekkinen Sr , Paavo J ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; REMACEMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

COGNITION; EPILEPSY; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0029899584     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605050-00005     Document Type: Article

References (95)

1. Neisser U. Cognition and reality. San Francisco: W.H. Freeman and Co., 1980
2. Dodrill CH. Behavioral effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble M, editors. Neurobehavioral problems in epilepsy. Advances in neurology. Vol. 55. New York: Raven Press, 1991: 213-24
3. Sutula TP, Cavazos JE, Woodard AR. Long-term structural and functional alterations induced in the hippocampus by kindling: implications for memory dysfunction and the development of epilepsy. Hippocampus 1994; 4: 254-8
4. Äikiä M, Kälviäinen R, Riekkinen Sr PJ. Verbal learning and memory in newly diagnosed partial epilepsy. Epilepsy Res 1995 Oct; 22: 157-64
5. Brodie MJ, McPhail E, Macphee GJA, et al. Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. Eur J Clin Pharmacol 1987; 31: 655-60
6. Kälviäinen R, Äikiä M, Helkala E-L, et al. Memory and attention in newly diagnosed epileptic seizure disorder. Seizure 1992; 1: 255-62
7. Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide veterans administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin and primidone. Epilepsia 1987; 28: 50-8
8. Engel J, Bandler R, Griffith NC, et al. Neurobiological evidence for epilepsy-induced interictal disturbances. In: Smith DB. Treiman DM, Trimble MR, editors. Neurobehavioral problems in epilepsy. New York: Raven Press, 1991: 97-111
9. Devinsky O. Cognitive and behavioral effects of antiepileptic. Epilepsia 1995; 36 Suppl. 2: 46-65
10. Dodrill CB. Cognitive and psychosocial effects of epilepsy on adults. In: Wyllie E, editor. The treatment of epilepsy: principles and practices. Philadelphia: Lea & Febiger, 1993; 1133-40
11. Loring DW, Meador KJ. Cognitive and behavioral effects of antiepileptic drugs issues in epilepsy and quality of life. Epilepsy Foundation of America, 1993
12. Meador KJ, Loring DW. Cognitive effects of antiepileptic drugs. In: Devinsky O, Theodore WH, editors. Epilepsy and behavior. New York: Wiley-Liss, 1991: 151-70
13. Smith DB. Cognitive effects of antiepileptic drugs. In: Smith D. Trehnan D, Trimble M, editors. Neurobehavioral problems in epilepsy. Advances in neurology. Vol 55. New York: Raven Press, 1991: 197-212
14. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28: 37-45
15. Durwen HE, Elger CE, Helmstaedter C, et al. Circumscribed improvement of cognitive performance in TLE patients with intractable seizures following reduction of anticonvulsant medication. J Epilepsy 1989; 2: 147-53
16. Durwen HF, Elger CE. Verbal differences in epileptic patients with left and right temporal lobe foci a pharmacologically induced phenomenon? Acta Neurol Scand 1993; 87: 1-8
17. Gaily EK, Granström ML, Hiilesmaa VK, et al. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 1990; 5: 217-22
18. Ransom BR, Elmore JG. Effects of antiepileptic drugs on the developing central nervous system In: Smith D, Treiman D, Trimble M, editors. Neurobehavioral problems in epilepsy. Advances in neurology. Vol. 55. New York: Raven Press, 1991: 225-37
19. Trimble MR, Reynolds EH. Anticonvulsant drugs and mental symptoms. Psychol Med 1976; 6: 169-78
20. Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. BMJ 1979; 2: 1023-5
21. Thompson P, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 1982; 23: 531-44
22. Dodrill CB. Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy. Epilepsia 1975; 16: 593-600
23. Thompson P, Trimble MR. Comparative effects of anticonvulsant drugs on cognitive functioning. Br J Clin Pract 1982; 18: 154-6
24. Thompson PJ, Trimble MR. Anticonvulsant serum levels: relationship to impairments of cognitive functioning. J Neurol Neurosurg Psychiatr 1983; 46: 227-33
25. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977; 27: 1023-8
26. Thompson PJ, Huppert FA. Trimble MR. Phenytoin and cognitive functions: effects on normal volunteers and implications for epilepsy. Br J Clin sychol 1981; 20: 155-62
27. Thompson PJ, Trimble MR. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981; 12: 819-24
28. Andrewcs DG, Bullen JG, Tomlinson L, et al. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 1986; 27: 128-34
29. Nichols ME, Meador KJ, Loring DW. Neuropsychological effects of antiepileptic drugs: a current perspective. J Clin Neuropharmacol 1993; 16: 471-84
30. Smith DB. Anticonvulsants, seizures and performance: the Veteran's Administration experience. In: Trimble MR, Reynolds EH, editors. Epilepsy, behaviour and cognitive function. Chichester: John Wiley & Sons Ltd, 1988: 67-78
31. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine and valproate on cognitive function. Epilepsia 1990; 31: 584-91
32. Gillham RA, Williams N, Wiedmann KD, et al. Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res 1990; 7: 219-25
33. Dodrill CB, Temkin NR. Motor speed is a contaminating factor in evaluating the cognitive effects of phenytoin. Epilepsia 1989; 30: 453-7
34. Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991; 41: 141-3
35. Dodrill CB, Wilensky AJ. Neuropsychological abilities before and after 5 years of stable antiepileptic drug therapy. Epilepsia 1992; 33: 327-34
36. Prevey ML, Delaney RC, Cramer JA, et al. Valproate versus carbamazepine: comparison of effects on cognitive functioning [abstract]. Epilepsia 1992; 33 Suppl. 3: 110
37. Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new eases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991; 33: 524-34
38. Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265: 1271-7
39. Smith KR, Goulding PM, Wilderman D, et al. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch Neurol 1994; 51: 653-60
40. Meador KJ, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990; 40: 391-4
41. Meador KJ, Loring DW, Allen MK, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991; 41: 1537-40
42. Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993; 34: 153-7
43. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenoharbital, phenytoin, and valproate in healthy adults. Neurology 1995; 45: 1494-9
44. Kälviäinen R, Keränen T, Riekkinen Sr PJ. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993; 46: 1009-24
45. Kälviäinen R, Riekkinen PJ. New antiepileptic drugs. Exp Opin Invest Drugs 1995; 4: 955-62
46. Chronopoulos A, Stafstrom C, Thurber S, et al. Neuroprotective effect of felbamate after kainic acid-induced status epileplicus. Epilepsia 1993; 43: 693-6
47. Wallis RA, Panizzon KL, Nolan JP. Glycine-induced CA1 excitotoxicity in the rat hippocampal slice. Brain Res 1994; 664: 115-25
48. Wasterlein CG, Adams LM, Hattori H, et al. Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur J Pharmacol 1992; 212: 275-8
49. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995: 36 Suppl. 2: 13-26
50. Ramsay RE. Clinical efficacy and safely of gabapentin. Neurology 1994; 44 Suppl. 4: 23-30
51. Saletu B, Grunberger J, Linzinayer L. Evaluation of encephalothrophic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry. Int J Clin Pharmacol Ther Toxicol 1986; 24: 362-73
52. Dodrill CB, Wilensky AJ, Ojemann LM. Neuropsychological, mood, and psychosocial effects of gabapentin [abstract]. Epilepsia 1992; 33 Suppl. 3: 117-8
53. Abou-Khalil B, McLean M, Castro O, et al. Gabapentin in the treatment of refractory partial seizures [abstract]. Epilepsia 1990; 31: 644
54. Handforlh A, Treiman DM, Norton LC. Effect of gabapentin on complex partial seizure frequency [abstract]. Neurology 1989; 39 Suppl. 1: 114
55. Ojeniann LM, Wilensky AJ, Temkin NR, et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992; 13: 159-65
56. Arnett JL, Dodrill CB. Effects of gabapentin on cognitive functioning and mood [abstract]. Epilepsia 1995; 36 Suppl. 3: 32
57. O'Donnell RA, Miller AA. The effect of lamotrigine upon development of cortical kindled seizures in the rat. Neuropharmacology 1991; 30: 253-8
58. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibonate lesions in rat striatum. Neurosci Lett 1990; 4: 348-51
59. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117-22
60. Cohen AF, Ashby L, Crowley D, et al. Lamotrigine (BW 430C), potential anticonvulsant: effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985; 20: 619-29
61. Hamilton MJ, Cohen AF, Yuen AWC, et al. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993; 34: 166-73
62. Mervaala E, Koivisto K, Hänninen T, et al. Electrophysiological and neuropsychological profiles of lamotrigine in young and age-associated memory impairment subjects [abstract]. Neurology 1995; 46 Suppl. 4: 259
63. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34: 312-22
64. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713
65. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 25: 476-9
66. Steiner TJ, Silveira C, Yuen AWC. Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy [abstract]. Epilepsia 1994; 35: 61
67. Grant S, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-88
68. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 1991; 29: 356-63
69. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993; 44: 529-33
70. Laaksonen R, Kaimola K, Grahn-Teräväinen E, et al. A controlled trial of the effects of carbamazepine and oxcarbazepine on memory and attention [abstract]. 16th International Epilepsy Congress; 1985: Hamburg.
71. Sabers A. The effect of carbamazepine, sodium-valproate and oxcarbazepine on neuropsychological functions in patients with epilepsy [abstract]. Acta Neurol Scand 1990; 82: 80
72. Äikiä M, Kälviäinen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992; 11: 199-203
73. Rogawski MA. The NMDA receptor, NMDA antagonists and epilepsy therapy: a status report. Drugs 1992; 44: 279-92
74. Bannan PE, Graham DI, Lees KR, et al. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res 1994; 664: 271-5
75. Ordy JM, Thomas GJ. Remacemide effects on memory and hippocampal CA1 neuronal damage in the rat four-vessel occlusion model of global cerebral ischemia [abstract]. Soc Neurosci Abstr 1991; 17: 1081
76. Jamieson V. Preclinical and early clinical experience: remacemide hydrochloride safety - anticonvulsant and neuroprotectant? Satellite symposium in 21st International Epilepsy Congress; 1995 Sept 4-8; Sydney
77. Halonen T, Nissinen J, Jansen J, et al. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur J Pharmacol. In press
78. Sveinbjornsdottir S, Sander JWAS, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3: 29-35
79. Dodrill C, Arnett JL, Sommerville K, et al. Tiagabine [abstract]. Epilepsia 1995; 36 Suppl. 3: 31
80. Kälviäinen R, Äikiä M, Mervaala E, et al. Long-term cognitive effects of tiagabine [abstract]. Epilepsia 1995; 36 Suppl. 3: 149
81. Privitera M. Long-term cognitive effects of topiramate [abstract]. Epilepsia 1995; 36 Suppl. 3: 152
82. Brooks J, Sachdeo R, Lim P. Topiramate: neuropsychometric assessments [abstract]. Epilepsia 1995; 36 Suppl. 3: 273
83. Shin C, Rigsbee LC, McNamnra JO. Anti-seizure and anti-epileptogenic effect of gamma-vinyl-gamma-aminobutyric acid in amygdaloid kindling. Brain Res 1986; 398: 370-4
84. Ylinen AMA, Miettinen R, Pitkänen A, et al. Enhanced GABA-ergic inhibition preserves hippocampal structure and function in a model of epilepsy. Proc Natl Acad Sci USA 1991; 88: 7650-3
85. Pitkänen A, Tuunanen J, Halonen T. Vigabatrin and carbamazepine have different efficacies in prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala. Epilepsy Res. In press
86. Dodrill CB, Arnett JL, Sommerville KW, et al. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993; 43: 2501-7
87. Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164-73
88. Gillham RA, Blacklaw J, McKee PJW, et al. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1993; 53: 1271-5
89. Grunewald RA, Thompson PJ, Corcoran R, et al. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry 1994; 57: 1057-63
90. McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992; 33: 128-34
91. Kälviäinen R, Äikiä M, Saukkonen AM, et al. Vigabatrin vs carbama/.epine monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995; 52: 989-96
92. Kälviäinen R, Äikiä M, Riekkinen PJ. Vigabatrin monotherapy in newly diagnosed patients with epilepsy: two-year comparative follow-up of efficacy, safety and cognitive effects [abstract]. Epilepsia 1995; 36 Suppl. 3: 105
93. Hamoda K, Ishida S, Yagi K. Anticonvulsant effects of zonisamide on amygdaloid kindling in rats. Neuroscience 1990; 16: 407-12
94. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
95. Berent S, Sackellares JC, Giordani B, et al. Zonisamide (Cl-912) and cognition: results from preliminary study. Epilepsia 1987; 28: 61-7